This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Managing CVD and Renal Disease in T2DM: Individualizing Treatment Using Guideline- and Evidence-based Data

Managing CVD and Renal Disease in T2DM: Individualizing Treatment Using Guideline- and Evidence-based Data

Format

Webcast

Time to Complete

1 hour

Released

July 19, 2019

Expires

July 19, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Jointly provided by Boston University School of Medicine and Rockpointe

Commercial Supporter

Supported by an educational grant from AstraZeneca.

Program Description

Type 2 diabetes mellitus (T2DM) is a significant public-health problem, as many patients do not achieve HbA1c goals. The disease can be further complicated by the presence of comorbidities, specifically cardiovascular and renal complications. Cardiovascular disease (CVD) remains the leading cause of death in patients with T2DM and chronic kidney disease increases the risk of CVD in those with T2DM. Reduction of cardiovascular risk through lifestyle interventions and pharmacologic therapies is critical.

In order to determine which agent is best to individualize therapy for each patient with T2DM and associated comorbidities, physicians must be kept up to date with the ongoing release of clinical-trial data and guideline updates on the cardiovascular and renal benefits of antihyperglycemic agents. Managing CVD and Renal Disease in T2DM: Individualizing Treatment Using Guideline- and Evidence-based Data will ensure physicians are aware of the profiles of antihyperglycemic agents for T2DM. The education will also review data from cardiovascular outcomes trials demonstrating reductions in CVD and renal complications with the use of certain antihyperglycemic agents in patients with T2DM.

Intended Audience

The primary intended audience for this educational activity is internal medicine physicians who manage patients with T2DM and its associated comorbidities.

Educational Objectives

This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this activity, participants should be able to:

  • Develop individualized management plans for patients with T2DM utilizing guideline and evidence-based recommendations
  • Evaluate blood pressure and lipid goals for patients with T2DM to decrease cardiovascular and renal comorbidities
  • Assess the benefits of newer antihyperglycemic agents in patients with T2DM and CVD and/or renal disease

Fee Information

There is no fee for this activity.

Conflict of Interest Disclosure Policy

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Jennifer B. Green, MD
Professor of Medicine
Duke University Medical Center, Division of Endocrinology
Duke Clinical Research Institute
Durham, NC

Dr. Green discloses the following:
Consultant: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi/Regeneron;
Grant/Research Support: Boehringer Ingelheim, Sanofi/Regeneron

Philip Raskin, MD, FACP, FACE, CDE
Professor of Medicine
Clifton and Betsy Robinson Chair in Biomedical Research
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Raskin discloses the following:
Consultant: Reata Pharmaceuticals, Inc.;
Research Support: Gan & Lee Pharmaceuticals; Novo Nordisk

Elliot Sternthal, MD, FACP, FACE (CME Course Director) has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Kathy Merlo; Blair St. Amand; Elizabeth Drury; and Natalie Sanfratello, MPH have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please email: cme@bu.edu.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue